Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1378 of 6351
-
Laser therapy aims to preserve sight in AMD patients
Disease control Recruiting nowThe goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors and reduces the progression of intermediate Age-rela…
Sponsor: OD-OS MacuTherm GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
One shot to tackle two heart risks? new combo drug enters human trials
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hyperc…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug AB801 aims to boost chemo and immunotherapy in tough cancers
Disease control Recruiting nowThis phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has sp…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Gene therapy for Parkinson's: will it last? new study tracks 6 patients over time
Disease control Recruiting nowThe purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Sponsor: Innopeutics Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study is a Phase Ib/II clinical study. It includes two stages: Phase Ib and Phase II. In the Phase Ib stage, the primary objective is to evaluate the safety and tolerability of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors, and…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets Hard-to-Treat cancer mutation in early human test
Disease control Recruiting nowThis is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a simple kit ease sexual pain for millions with endometriosis?
Symptom relief Recruiting nowEndometriosis is a complex gynecological condition that affects approximately 10% of women of reproductive age, according to 2023 data from the World Health Organization. Endometriosis is often associated with debilitating pain, particularly during sexual intercourse (dyspareunia…
Sponsor: Elsan • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug SLN12140 aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of SLN12140 at different doses in IgA nephropathy subj…
Phase 2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can a new infrared camera help surgeons spot nerves and bile ducts?
Knowledge-focused By invitation onlyThe goal of this observational study is to perform an in-human assessment of an investigational shortwave infrared (SWIR) imaging device, aimed to enhance the visualization of critical anatomical structures during surgical procedures in non-vulnerable adults between the ages of 1…
Sponsor: Cision Vision, Inc. • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A\*02:01-positive and MAGE-A1-positive advanced solid tumors. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and …
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
One-Shot gene therapy could simplify cancer treatment
Disease control Recruiting nowThis is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of IASO207 Injection in patients with Relapsed/Refractory B-cell Malignancies。
Early phase 1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New sensor could help preterm babies breathe easier
Diagnosis Recruiting nowExtremely preterm infants, born before 29 weeks of pregnancy, often face breathing difficulties, also known as respiratory events, due to their undeveloped lungs and respiratory systems. These respiratory events include pauses in breathing, shallows breaths, and irregular breathi…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Diagnosis
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat leukemia
Disease control OngoingThe goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes. The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 ca…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Spinal zaps and drug combo aim to boost mobility in kids with cerebral palsy
Disease control Recruiting nowThis is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participant…
Phase 2 • Sponsor: Shirley Ryan AbilityLab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill hopes to tame severe gut disease in kids
Disease control Recruiting nowThe purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \< 12 years of age). Participants who will complete the total 5…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New pill could help shed pounds: obesity drug trial begins
Disease control Recruiting nowThe primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
Phase 2 • Sponsor: ERX Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart brace could keep Kids' spines straight without surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if the RESILIENT Scoliosis Brace System works to treat children with idiopathic scoliosis. It will also learn about the safety, comfort, and usability of the brace. The main questions it aims to answer are: * Can the RESILIENT brace pr…
Sponsor: Thinks Works, PBC • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThe purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New exercise program aims to reverse frailty in seniors
Disease control Recruiting nowFrailty is a multidimensional clinical syndrome associated with increased vulnerability to adverse health outcomes in older adults. Despite strong evidence supporting multicomponent exercise interventions, their implementation in primary care settings remains limited. This rando…
Sponsor: Alberto Bermejo Franco • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Wearable sensors and blood markers may predict delirium in intensive care
Knowledge-focused Recruiting nowThe goal of this observational study is to learn if there are potential digital and plasma-based biomarkers that could help detect, predict, and prognosticate delirium in older adult patients who are admitted to the intensive care unit (ICU). The main question DELTA aims to answe…
Sponsor: Scripps Health • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC